Key Points
- Ra Capital Management sold 4,175,139 shares of Fulcrum Therapeutics on Dec. 8 at an average of $13.98, totaling about $58.37M and reducing its position by 40.82% to 6,053,960 shares (~$84.63M).
- Fulcrum has a market cap near $746.9M, a one‑year range of $2.32–$15.74, recently reported a quarterly EPS loss of ($0.31) that missed estimates, and carries a mixed analyst consensus with an average target of $18.50.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the sale, the insider owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. This represents a 40.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Fulcrum Therapeutics Price Performance
Fulcrum Therapeutics stock opened at $13.80 on Thursday. The firm has a market capitalization of $746.86 million, a P/E ratio of -11.69 and a beta of 3.17. Fulcrum Therapeutics, Inc. has a one year low of $2.32 and a one year high of $15.74. The business has a fifty day moving average price of $9.65 and a 200-day moving average price of $8.03.
Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.02). Sell-side analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Fulcrum Therapeutics
Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC boosted its holdings in shares of Fulcrum Therapeutics by 865.0% in the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company's stock worth $989,000 after purchasing an additional 308,854 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Fulcrum Therapeutics during the 1st quarter valued at about $425,000. Exome Asset Management LLC lifted its position in Fulcrum Therapeutics by 143.0% in the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company's stock worth $1,985,000 after buying an additional 405,538 shares during the last quarter. Strs Ohio bought a new stake in Fulcrum Therapeutics in the 1st quarter worth approximately $263,000. Finally, XTX Topco Ltd purchased a new stake in Fulcrum Therapeutics in the first quarter worth approximately $144,000. Institutional investors own 89.83% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on FULC shares. Bank of America raised their price objective on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an "underperform" rating in a research report on Tuesday. Truist Financial set a $14.00 target price on shares of Fulcrum Therapeutics in a research note on Monday, November 24th. The Goldman Sachs Group restated a "positive" rating on shares of Fulcrum Therapeutics in a research report on Monday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 1st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $18.50.
Check Out Our Latest Research Report on Fulcrum Therapeutics
Fulcrum Therapeutics Company Profile
(
Get Free Report)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
